This study finds that neoadjuvant chemotherapy may actually increase genomic radioresistance among hormone receptor positive and HER2 negative breast cancers. In a cohort of 30 patients with pretreatment and posttreatment RNA sequencing data, 76% had an increase in their Radiation Sensitivity Index (RSI) after neoadjuvant therapy. | Loap, Adv Radiat Oncol 2026
